NOVOGEN LIMITED
(ASX: NRT)

ASX RELEASE
5 MAY 2014

Novogen Joins Children's Oncology Drug Alliance (CODA) to Facilitate Development of Treatments for Childhood Cancers

Alliance of Australian and U.S. researchers and children's cancer advocates focused on developing drugs as potential treatments for childhood cancers

SYDNEY May 5, 2014 – Novogen has joined with researchers and children's cancer advocates in Australia and the U.S. to form a unique research and development alliance to facilitate development of treatments for children with cancer.

The Children's Oncology Drug Alliance (CODA) unites Novogen with

- The University of New South Wales in Australia (UNSW)
- The Kids' Cancer Project (TKCP), an Australia-based childhood cancer research charity, and
- The Nationwide Children's Hospital in Columbus, Ohio.

CODA's mission is to help accelerate development of innovative new therapeutic approaches to the treatment of chlldhood cancers, but neuroblastoma in particular.

"For too long, childhood cancers have been neglected despite the progress made with treatments for adult cancers. The Alliance brings together the science, expertise and funding to accelerate the development of a medicine that has the potential to change the way we treat solid cancers in children," said Professor Peter Gunning, Head of the Oncology Research Unit at UNSW Faculty of Medicine.

Currently there is no approved treatment for neuroblastoma, a cancer that affects up to 100 children in Australia and around 650 in the United States each year. Childhood cancers currently are treated with chemotherapies that have been developed for adults, with little consideration to the special needs of children.

Novogen is providing access to its anti-tropomyosin and super-benzopyran drug technologies to facilitate the development of the first chemotherapy regime approved for the treatment of childhood solid cancers such as neuroblastoma.

"The Holy Grail of childhood cancer therapy is a medicine that is effective against a tumour such as neuroblastoma, but doesn't leave the sort of damage that the child then has to deal with for the rest of his or her life," Novogen CEO, Dr. Graham Kelly, said. "We believe that the two drug technologies we have developed have the potency, selectivity and safety profile to meet the special needs of children," he said.

"We are making available both our anti-tropomyosin and super-benzopyran drug technologies for this great cause," Kelly added.

Novogen is currently finalizing pre-clinical research of its two lead drug candidates, with the goal of starting clinical studies in Australian and U.S. patients in 2015. The aim is that the childhood trials in

neuroblastoma will be progressed in parallel with trials of anti-tropomyosins and super-benzopyrans for a number of adult cancers.
The clinical trials due to start in the U.S. and Australia next year are the first important step towards this treatment becoming available to patients on a general basis; the process of which is expected to take a number of years.

About Neuroblastoma
Neuroblastoma is a cancer that develops from immature nerve cells found in several areas of the body. Neuroblastoma most commonly arises in and around the adrenal glands, which have similar origins to nerve cells and sit atop the kidneys. However, neuroblastoma can also develop in other areas of the abdomen and in the chest, neck and near the spine, where groups of nerve cells exist. Neuroblastoma most commonly affects children age 5 or younger, though it may rarely occur in older children. Some forms of neuroblastoma go away on their own, while others may require multiple treatments.

About Novogen
Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer, ovarian cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing an intra-peritoneal product for late-stage ovarian cancer.

Further information on CODA is available at www.childrensoncologydrugalliance.org

Further information on Novogen is available on the Company's website, www.novogen.com.

Contact

In Australia
Jay Pleass
Ethical Strategies
(0412 623 578)
John Morton
02 8904 7300

In ROW
Sue Charles/Stefanie Bacher
Instinctif Partners
+44 (0)20 7457 2020

In the USA
Hollister Hovey/Allison Parks
Lazar Partners
+ 1 212-867-1762
Novogen@lazarpartners.com